$23.99
1.65% yesterday
Nasdaq, Aug 12, 10:00 pm CET
ISIN
US0453961080
Symbol
ASMB

Assembly Biosciences, Inc. Stock price

$23.99
+5.15 27.34% 1M
+11.42 90.85% 6M
+8.21 52.03% YTD
+10.92 83.55% 1Y
-1.57 6.14% 3Y
-225.61 90.39% 5Y
-139.45 85.32% 10Y
-354.01 93.65% 20Y
Nasdaq, Closing price Tue, Aug 12 2025
+0.39 1.65%
ISIN
US0453961080
Symbol
ASMB
Industry

Key metrics

Basic
Market capitalization
$181.1m
Enterprise Value
$106.1m
Net debt
positive
Cash
$75.0m
Shares outstanding
7.7m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
5.4 | 6.3
EV/Sales
3.2 | 3.7
EV/FCF
negative
P/B
10.0
Financial Health
Equity Ratio
28.0%
Return on Equity
-120.4%
ROCE
-130.0%
ROIC
121.1%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$33.3m | $28.5m
EBITDA
$-43.4m | $-46.6m
EBIT
$-43.5m | $-44.7m
Net Income
$-39.0m | $-38.5m
Free Cash Flow
$-55.9m
Growth (TTM | estimate)
Revenue
54.8% | 0.0%
EBITDA
13.7% | -2.9%
EBIT
13.9% | 1.6%
Net Income
14.6% | 4.2%
Free Cash Flow
-331.7%
Margin (TTM | estimate)
Gross
-
EBITDA
-130.5% | -163.4%
EBIT
-130.9%
Net
-117.2% | -134.9%
Free Cash Flow
-168.0%
More
EPS
$-5.1
FCF per Share
$-7.3
Short interest
0.6%
Employees
73
Rev per Employee
$390.0k
Show more

Is Assembly Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.

Assembly Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Assembly Biosciences, Inc. forecast:

7x Buy
78%
2x Hold
22%

Analyst Opinions

9 Analysts have issued a Assembly Biosciences, Inc. forecast:

Buy
78%
Hold
22%

Financial data from Assembly Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
33 33
55% 55%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 18 18
18% 18%
54%
- Research and Development Expense 59 59
18% 18%
177%
-43 -43
14% 14%
-130%
- Depreciation and Amortization 0.13 0.13
50% 50%
0%
EBIT (Operating Income) EBIT -44 -44
14% 14%
-131%
Net Profit -39 -39
15% 15%
-117%

In millions USD.

Don't miss a Thing! We will send you all news about Assembly Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Assembly Biosciences, Inc. Stock News

Positive
Seeking Alpha
4 days ago
Assembly Biosciences, Inc.'s ABI-5366 showed strong interim phase 1b results in HSV-2 recurrent genital herpes patients, with a 94% reduction in HSV-2  shedding and genital lesion rates. Upcoming catalysts include monthly dosing data for ABI-5366 and phase 1b data for ABI-1179, both expected in fall 2025, plus potential Gilead opt-in milestones. ASMB addresses a major unmet need, as no new HSV-...
Neutral
GlobeNewsWire
5 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (“Assembly Bio”) (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced the pricing of an underwritten, registered offering (the “offering”) of an aggregate of 5,591,840 shares of common stock and pre-funded warrants to purchase up to 1,...
Neutral
GlobeNewsWire
5 days ago
– 94% reduction in HSV-2 shedding rate and 98% reduction in high viral load shedding rate, both statistically significant, observed in cohort evaluating 350 mg weekly oral dose compared to placebo over 29-day evaluation period – – 94% reduction in genital lesion rate, also statistically significant, observed with 350 mg weekly oral dose compared to placebo over same period – – Favorable safety ...
More Assembly Biosciences, Inc. News

Company Profile

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses in two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Head office United States
CEO Jason Okazaki
Employees 73
Founded 2005
Website www.assemblybio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today